Vlok Ruan, Buscher Hergen, Delaney Anthony, Garside Tessa, McDonald Gabrielle, Chatoor Richard, Myburgh John, Nair Priya
Royal North Shore Hospital, Intensive Care Unit, Sydney, Australia.
The George Institute for Global Health, Critical Care Program, Australia.
Crit Care Resusc. 2024 Nov 26;26(4):332-363. doi: 10.1016/j.ccrj.2024.10.003. eCollection 2024 Dec.
To describe the incidence of bleeding and thrombotic complications in VA-ECMO according to anticoagulation strategy.
This systematic review and meta-analysis included randomised controlled trials (RCTs) and observational studies reporting bleeding and thrombotic complications in VA-ECMO. The incidence of primary outcomes according to anticoagulation drug and monitoring test was described.
CENTRAL, MEDLINE, Embase and CINAHL (2010-January 2024).
Data was extracted using Covidence. A meta-analysis of proportions was performed using STATA MP v18.1 metaprop.
We included 159 studies with 21,942 patients. No studies were at low risk of bias. The incidence of major bleeding or thrombotic events was similar among heparin-, bivalirudin- and anticoagulation-free cohorts. The pooled incidence of major bleeding and thrombotic complications were 40% (95%CI 36-44, I = 97.12) and 17% (95%CI 14-19, = 92.60%), respectively. The most common bleeding site was thoracic. The most common ischaemic complication was limb ischaemia. The incidences of major bleeding or thrombotic events, intracranial haemorrhage and ischaemic stroke were similar among all monitoring tests. Mechanical unloading was associated with a high incidence of major bleeding events (60%, 95%CI 43-77, I = 93.32), and ischaemic strokes (13%, 95%CI 7-19, I = 81.80).
Available literature assessing the association between anticoagulation strategies in VA-ECMO, and bleeding and thrombosis is of limited quality. We identified a substantially higher incidence of major bleeding events than a previous meta-analysis. Limited numbers of patients anticoagulated with alternatives to heparin were reported. Patients with additional mechanical LV unloading represent a cohort at particular risk of bleeding and thrombotic complications.
根据抗凝策略描述静脉-动脉体外膜肺氧合(VA-ECMO)中出血和血栓形成并发症的发生率。
本系统评价和荟萃分析纳入了报告VA-ECMO中出血和血栓形成并发症的随机对照试验(RCT)和观察性研究。描述了根据抗凝药物和监测检查得出的主要结局的发生率。
CENTRAL、MEDLINE、Embase和CINAHL(2010年1月至2024年)。
使用Covidence提取数据。使用STATA MP v18.1的metaprop进行比例的荟萃分析。
我们纳入了159项研究,共21942例患者。没有研究处于低偏倚风险。肝素、比伐卢定和无抗凝治疗队列中,大出血或血栓形成事件的发生率相似。大出血和血栓形成并发症的合并发生率分别为40%(95%CI 36-44,I² = 97.12)和17%(95%CI 14-19,I² = 92.60%)。最常见的出血部位是胸部。最常见的缺血性并发症是肢体缺血。所有监测检查中,大出血或血栓形成事件、颅内出血和缺血性卒中的发生率相似。机械卸载与大出血事件(60%,95%CI 43-77,I² = 93.32)和缺血性卒中(13%,95%CI 7-19,I² = 81.80)的高发生率相关。
评估VA-ECMO抗凝策略与出血和血栓形成之间关联的现有文献质量有限。我们发现大出血事件的发生率比之前的荟萃分析显著更高。报告中使用肝素替代物抗凝的患者数量有限。接受额外左心室机械卸载的患者是出血和血栓形成并发症的特别高危人群。